Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 4.

Simic, Branko; Mocharla, Pavani; Crucet, Margot; Osto, Elena; Kratzer, Adelheid; Stivala, Simona; Kühnast, Susan; Speer, Thimoteus; Doycheva, Petia; Princen, Hans M; van der Hoorn, Jose W; Jukema, J Wouter; Giral, Hector; Tailleux, Anne; Landmesser, Ulf; Staels, Bart; Lüscher, Thomas F (2017). Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase. Atherosclerosis, 257:186-194.

Kühnast, Susan; van der Tuin, Sam J L; van der Hoorn, José W A; van Klinken, Jan B; Simic, Branko; Pieterman, Elsbet; Havekes, Louis M; Landmesser, Ulf; Lüscher, Thomas F; Willems van Dijk, Ko; Rensen, Patrick C N; Jukema, J Wouter; Princen, Hans M G (2015). Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin. European Heart Journal, 36(1):39-50.

Spescha, Remo D; Glanzmann, Martina; Simic, Branko; Witassek, Fabienne; Keller, Stephan; Akhmedov, Alexander; Tanner, Felix C; Lüscher, Thomas F; Camici, Giovanni G (2014). Adaptor protein p66(Shc) mediates hypertension-associated, cyclic stretch-dependent, endothelial damage. Hypertension, 64(2):347-353.

Lüscher, Thomas F; von Eckardstein, Arnold; Simic, Branko (2012). Therapeutic targets to raise HDL in patients at risk or with coronary artery disease. Current Vascular Pharmacology, 10(6):720-724.

This list was generated on Wed Jun 19 20:25:15 2019 CEST.